Evidence map›Paper›PMID 42435280›Full record

ArticleInternational journal of clinical oncology2026

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy.

Takeshi Sasaki, Shinichiro Higashi, Kouhei Nishikawa, Koji Iinuma, Keita Nakane, Tomoki Taniguchi, Yuta Sano, Aika Matsuyama, Kaori Ozawa, Kosuke Tochigi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takeshi SasakiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Shinichiro HigashiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Kouhei NishikawaDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Koji IinumaDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Keita NakaneDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Tomoki TaniguchiDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yuta SanoDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Aika MatsuyamaDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kaori OzawaDepartment of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
Kosuke TochigiDepartment of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan.
Masataka TamuraDepartment of Urology, Okazaki City Hospital, Okazaki, Aichi, Japan.
Yasuaki KubotaDepartment of Urology, Toyota Memorial Hospital, Toyota, Aichi, Japan.
Shusuke AkamatsuDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Takuya KoieDepartment of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
Takahiro InoueDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. tinoue28@med.mie-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigated whether neutrophil-to-lymphocyte ratio (NLR) kinetics, including changes within the first week after the initiation of first-line combination immunotherapy, are associated with overall survival (OS) in patients with advanced renal cell carcinoma (aRCC).

methodsConsecutive patients with aRCC treated with first-line immune checkpoint inhibitor combination therapy at 12 Japanese institutions were included in this retrospective study. The NLR was assessed at baseline (BL), within 7 days (D7), and 1 month (M1) after treatment initiation. Patients were classified into three groups according to NLR at BL and at D7 as follows: BL NLR low (< 3), NLR high-low (BL NLR ≥ 3 and D7 NLR < 3), and NLR high-high (BL NLR ≥ 3 and D7 NLR ≥ 3) groups.

resultsIn total, 198 patients were included in the study, with a median follow-up of 18.0 months. The median NLR changed during follow-up at BL, D7, and M1 (BL, 3.28; D7, 3.23; M1, 2.74). OS stratified by NLR at each time point was significant at BL and D7, but not at M1. Among patients with BL NLR ≥ 3 (55%, n = 109), 26 patients (24%) had D7 NLR < 3. The 2 year OS rates were 83.7, 85.5, and 66.0% for patients in the low-, high-low-, and high-high groups, respectively. Multivariate analysis revealed that high NLR was an independent risk factor associated with worse OS.

conclusionsThe combination of BL NLR and D7 NLR identified high-risk patients with aRCC treated with first-line immune checkpoint inhibitor therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsLymphocytesNeutrophilsAdultAgedAged, 80 and overFemaleHumansImmunotherapyMaleMiddle AgedPrognosisRetrospective StudiesImmune Checkpoint InhibitorsImmunotherapyNeutrophil-to-lymphocyte ratioOverall survivalRenal cell carcinoma

Identifiers

PMID42435280
PMCPMC13506512

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.